Tovecimig Phase 2/3 Study Shows Significant PFS Benefit, Company Plans BLA Submission for Biliary Tract Cancer

summarizeSummary

Compass Therapeutics announced positive topline secondary endpoint data from its Phase 2/3 COMPANION-002 study for tovecimig in biliary tract cancer, demonstrating a highly statistically significant improvement in progression-free survival and plans for a Biologics License Application submission.

check_boxKey Events

• Significant Progression-Free Survival (PFS) Improvement

  Tovecimig in combination with paclitaxel demonstrated a highly statistically significant improvement in median PFS of 4.7 months compared to 2.6 months for paclitaxel alone (HR=0.44, p<0.0001) in the COMPANION-002 study for biliary tract cancer (BTC).

• Overall Survival (OS) Endpoint Not Met Due to Crossover

  The study did not meet its OS secondary endpoint in the intent-to-treat analysis (8.9 months vs. 9.4 months). This was attributed to a high crossover rate (54%) from the control arm to the tovecimig arm, with crossover patients showing prolonged survival.

• Benefit Observed in Crossover Patients

  Post-hoc analysis revealed that crossover patients who subsequently received tovecimig demonstrated a statistically significant improvement in median OS of 12.8 months compared to 6.1 months for non-crossover patients in the control arm (HR=0.54, p=0.04).

• Planned Biologics License Application (BLA) Submission

  Compass Therapeutics intends to meet with the U.S. Food and Drug Administration (FDA) to discuss these data in advance of a planned BLA submission for tovecimig in second-line BTC.

auto_awesomeAnalysis

This 8-K details critical clinical trial results for Compass Therapeutics' lead candidate, tovecimig, in biliary tract cancer. The highly statistically significant improvement in Progression-Free Survival (PFS) is a strong positive signal, indicating a meaningful delay in disease progression. While the Overall Survival (OS) endpoint was not met in the intent-to-treat analysis, the company provided a compelling explanation regarding the high crossover rate from the control arm to the active treatment arm, which likely diluted the OS benefit in the primary analysis. Furthermore, the post-hoc analysis showing significantly improved OS in crossover patients who received tovecimig reinforces the drug's potential benefit. The planned Biologics License Application (BLA) submission to the FDA is a major step towards potential commercialization and indicates the company's confidence in the data. This data could position tovecimig as a significant treatment option for patients with second-line BTC, an area with high unmet medical need.